Jefferies Financial Group Inc. Cassava Sciences Inc Call Options Transaction History

Jefferies Financial Group Inc.

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$9.57 - $35.08 $1,914 - $7,016	200 Added 1.9%	10,700 $314,000
Q2 2024 Aug 13, 2024	BUY	$12.35 - $26.11 $129,675 - $274,155	10,500 New	10,500 $129,000
Q4 2023 Feb 13, 2024	BUY	$12.64 - $30.11 $73,312 - $174,638	5,800 Added 15.89%	42,300 $952,000
Q1 2023 May 15, 2023	SELL	$23.46 - $36.44 $3.01 Million - $4.68 Million	-128,300 Reduced 77.85%	36,500 $880,000
Q4 2022 Sep 21, 2023	BUY	$27.82 - $44.16 $3.57 Million - $5.67 Million	128,300 Added 351.51%	164,800 $4.87 Million
Q4 2022 Feb 14, 2023	BUY	$27.82 - $44.16 $4.58 Million - $7.28 Million	164,800 New	164,800 $4.87 Million

196

13.8M

2.98M

6.57M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $101M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Jefferies Financial Group Inc., based on Form 13F filings with the SEC.

Stay updated on Jefferies Financial Group Inc. with notifications on news.